A ‘Better Botox’ May Target Millennials, Men and Hesitant Women
- Revance to report results in plantar fasciitis before year end
- RT002 appears to outlast the competition in late-stage testing
A vial of Allergan Botox, produced by Allergan Inc.
Photographer: Jason Alden/Bloomberg
This article is for subscribers only.
Revance Therapeutics Inc’s lead asset is a new form of botulinum toxin, akin to the best-selling wrinkle eraser, Botox, but with a key difference, durability, according to Chief Executive Officer Daniel Browne.
Recent results in a late-stage study may back up his claim. The Newark, California-based drug developer plans to leverage that durability claim to expand into previously untapped markets rather than just challenging Botox and its maker, Allergan Plc, Browne said in an interview at Bloomberg LP’s New York office.